Download presentation
Presentation is loading. Please wait.
Published byNikolett Somogyi Modified over 6 years ago
1
The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: Results from a population-based cohort in Eastern Europe Peter L. Lakatos, Barbara D. Lovasz, Gyula David, Tunde Pandur, Zsuzsanna Erdelyi, Gabor Mester, Mihaly Balogh, Istvan Szipocs, Csaba Molnar, Erzsebet Komaromi, Petra A. Golovics, Zsuzsanna Vegh, Michael Mandel, Agnes Horvath, Miklos Szathmari, Lajos S. Kiss, Laszlo Lakatos Journal of Crohn's and Colitis Volume 7, Issue 5, Pages (June 2013) DOI: /j.crohns Copyright © 2012 European Crohn's and Colitis Organisation Terms and Conditions
2
Figure. 1 Overall rate of lymphoma in patients with IBD.
SIRIBD: 1.37, 95% CI: 0.44–4.26. SIRUC: 1.35, 95% CI: 0.34–5.42. SIRIBD: 1.41, 95% CI: 0.20–10.1. Journal of Crohn's and Colitis 2013 7, DOI: ( /j.crohns ) Copyright © 2012 European Crohn's and Colitis Organisation Terms and Conditions
3
Figure. 2 Overall incidence rate of lymphoma in male patients with IBD. SIRmale: 2.40, 95% CI: 0.77–7.47. Journal of Crohn's and Colitis 2013 7, DOI: ( /j.crohns ) Copyright © 2012 European Crohn's and Colitis Organisation Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.